Status of Ongoing Proceedings

For information on how to obtain public transcripts of proceedings, please contact the Registrar, Riaz Awadia, by phone at 613-288-9597 or by e-mail at Riaz.Awadia@pmprb-cepmb.gc.ca.

Dates of Upcoming Hearings or Pre-Hearing Conferences

blank
Case Event Date / Location
Procysbi – Horizon Therapeutics Canada Hearing

November 23 – 26, 2020
November 30 – December 3, 2020

The Hearing will take place using the Zoom platform and will be livestreamed on YouTube.
To participate as an Observer, please send an email no later than 4:00pm on November 19, 2020 stating your name, email address and phone number to the Secretariat at
Riaz.awadia@pmprb-cepmb.gc.ca

Matters before the Board

Excessive Pricing
Patented Drug Product Indication / Use Patentee Issue Date of Notice of Hearing Status
Procysbi nephropathic cystinosis Horizon Therapeutics Canada Allegations of excessive pricing February 27, 2019
Case Management
Differin
Differin XP
Acne Galderma Canada Inc. Failure to file (jurisdiction)  
  • FCA sent back matter to PMPRB’ Board Panel for RE-determination on June 28, 2019
  • Written submissions RE impact of decision on Panel’s re-determination filed by both parties on July 31, 2019.

Judicial Review of Board Decisions and Appeals

Patented Drug Product Indication / Use Patentee Issue Date of Notice of Application Status
Soliris Paroxysmal Nocturnal Hemoglobinuria

Atypical Hemolytic Uremic Syndrome
Alexion Pharmaceuticals Inc. Allegations of excessive pricing January 20, 2015 Court File A-237-19 (RE T-1596-17 Board Panel’s decision of Sept 20, 2017)
  • Notice of Appeal filed by Alexion, June 21, 2019
Differin Differin XP Acne Galderma Canada Inc. Failure to file (jurisdiction) February 23, 2016 Court File A-385-17
  • Decision rendered June 28, 2019 sending back the file to PMPRB’s Board Panel for Re-determination
Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: